High Prevalence of Infectious Disease Is Accelerating the Growth of the Conjugate Vaccine Market

 

Conjugate Vaccine Market

A conjugate vaccine can be defined as a kind of vaccine that combines a pair of proteins that stimulate the immune system to produce antibodies against a specific virus or bacteria. These shots are made from a combination of a common virus-like measles and a virus that cause the common cold, like the swine flu. A conjugate vaccine has become one of the most efficient and strongest forms of prevention and treatment against these types of dangerous viruses. Scientists have been trying for several years to develop a vaccine that would be able to provide complete protection against all known viruses

The growing prevalence of the infectious disease is one of the prime factors driving the growth of the conjugate vaccine market. According to the World Health Organization, every year, 10 million people fall ill with tuberculosis (TB). Despite being a preventable and curable disease, 1.5 million people die from tuberculosis each year – making it the world’s top infectious killer. Most of the people who fall ill with TB live in low- and middle-income countries, but tuberculosis is present all over the world. Increasing technological advancement in the field of developing vaccines coupled with the growing global healthcare expenditure is again augment the growth of the market. Growing sale of meningococcal vaccines and pneumococcal vaccines due to rising awareness regarding the prevention of the disease is also projected to foster the growth of the conjugate vaccine market.

North America is projected to gain significant growth over the forecast period and this is attributed to the high prevalence of the infectious disease in the region coupled with the strong presence of a well-established healthcare sector. According to the National Institute of Allergy and Infectious Diseases, 50,000 new cases of HIV infections occur annually in the U.S., and nearly 33 million people are infected with HIV in the world. About 36,000 people per year in the U.S. die from influenza and pneumonia

Key Developments:

1.     In December 2020, Serum Institute of India, announces the launch of India's first indigenously developed pneumococcal vaccine - PNEUMOSIL.

2.     In March 2020, Pfizer Inc. announced top-line results from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate in adults 18 years of age or older not previously vaccinated against pneumococcal disease.

3.     In April 2020, The U.S. Food and Drug Administration (FDA) has approved a Biologics License Application for MenQuadfiTM Meningococcal (Groups A, C, Y, W) Conjugate Vaccine for the prevention of invasive meningococcal disease in persons 2 years of age and older.

 

 

Comments

Post a Comment

Popular posts from this blog

The Emergence of COVID-19 to Augment Growth of the Outsourced Drug Discovery Market

Image
  With billions of dollars in research and development costs, pharmaceutical companies around the world are always looking for new ways to address their production processes in a cost-effective manner. One way to achieve this is through outsourcing drug discovery and development services. This type of service refers to the collaboration between small and large biotech and biotechnology companies to conduct research and development activities aimed at finding better solutions to the company's core chemical concerns. Outsourcing of these drug discovery services has enabled established pharmaceutical and biotechnology companies to focus on the development of new products that can bring about significant therapeutic change and provide tangible advantages to the company's shareholders. Contract research organizations manage almost all aspects of drug discovery. Market Dynamics I ncreasing demand for outsourcing analytical testing and clinical trial services, growing R&D ex
Read more

Otoscope Market Is Gaining Major Traction with Industry Leader Otonexus Medical Technologies Introducing Ultrasound Sensor, Which Aids Middle-Ear Infection Diagnosis

Image
  An otoscope or auricular ear picker is a simple health care tool that is used to inspect the outer ear. Many health care professionals utilize otoscopes to examine ear infections during routine check-ups and to also screen for serious ear disorders. An otoscope possibly provides a more detailed view of the external ear canal and/or ear drum or eardrum. Otoscope or also referred to as auriscope is mainly used to look into eyes. The demand for these medical devices has been on a rise in the recent past. This is typically due to the fact that there is a high burden of ENT-related diseases across the globe. As per the World Health Organization (WHO), by 2050, around 2.5 billion people are estimated to have some degree of hearing loss worldwide. Similarly, there is a heavy burden of sinusitis cases. As per the Sinusitis & Allergy Wellness Center, around 30 million adults in the U.S. are impacted with sinusitis annually. Such a high prevalence of ENT disorders has accelerated the deman
Read more

The Number of Cancer Survivors Is Projected To Increase to 22.2 Million By 2030 Fostering Oncology Drug Pipeline Analysis Market

Image
  North America is estimated to dominate the global oncology drug pipeline analysis market in the near future and this is attributed to the high prevalence of cancer and increasing launch of various novel drugs with improved efficacy. According to the National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors in the United States. The number of cancer survivors is projected to increase to 22.2 million by 2030. The oncology field is experiencing significant growth and this is attributed to the increasing development of various novel therapies for the treatment of cancer. For instance, in February 2021, Rhizen Pharmaceuticals AG, a clinical-stage, oncology-focused biopharma company, with a 50% stake owned by Alembic Pharmaceuticals and the rest by its Indian CEO Swaroop Vakkalanka, has announced that its the novel, next-generation PI3K-delta inhibitor Umbralisib (Ukoniq) has secured U.S. FDA accelerated approval for the treatment of blood cance
Read more